NanoString Technologies Announces Key Executive Management Appointments
Brad Gray Joins as President and Chief Executive Officer, and Nalini Murdter Named Chief Business Officer
SEATTLE, Wash | June 29, 2010 NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced that it has appointed Brad Gray as President and Chief Executive Officer, and Nalini Murdter, Ph.D. as Chief Business Officer.
Brad Gray joins NanoString from Genzyme Genetics, the diagnostic services division of Genzyme Corporation, where he was most recently Vice President of Product & Business Development leading the development of molecular diagnostics and partnering activities. Mr. Gray held several strategy and business development roles at the corporate and division levels beginning in 2004 when he joined Genzyme Corporation as Director of Corporate Development. Previously, Mr. Gray was a management consultant in the healthcare practice of McKinsey & Company. He holds a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.
“NanoString Technologies has a rapidly growing research instrument and consumables business, and one of the most promising technology platforms available for high-value molecular diagnostics,” said Mr. Gray. “I look forward to working with the NanoString team to continue our success in the research market while aggressively expanding into clinical diagnostics.”
Dr. Murdter brings twenty years of experience in the life sciences and clinical diagnostics sectors. She joined NanoString from Agilent Technologies where she held several senior management positions in business development, strategy and marketing including Sr. Director of Acquisitions, Alliances and Ventures and most recently Global Product Marketing Manager in the Life Sciences and Chemical Analysis division. Prior to Agilent, Nalini was with Adeza Biomedical (later acquired by Cytyc/Hologic). As the Director of Product and Business Development, she led the development and commercialization of clinical diagnostic products and closed key licensing and commercialization deals. She was a Senior Research Fellow at the California Institute of Technology. Dr. Murdter received a Ph.D. in Biochemistry from the University of Maryland, and an M.B.A. from the Haas School of Business at UC Berkeley.
“We are delighted to welcome Brad and Nalini to our growing management team as we continue to execute on our strategy to expand the company’s focus into the emerging field of molecular diagnostics,” said William D. Young, Executive Chairman of NanoString Technologies. “Both executives bring to the team deep knowledge of the life sciences market as well as broad business strategy experience that will be highly valuable as we evaluate the various commercialization and partnering opportunities available to us.”
For more information, please visit www.nanostring.com.
About NanoString Technologies, Inc.
NanoString Technologies is a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples. The company’s nCounter® Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.